MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

ABBV · NYSE

AbbVie Inc.

Health Care · Biotechnology: Pharmaceutical Preparations

Reference price$263.20As of Jul 28, 2026
Market capitalization$465B
52-week range$187.62–$262.10
S&P 500 portfolio weight0.71%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$225.00-14.5% vs. reference
Average$271.38+3.1% vs. reference
High$300.00+14.0% vs. reference
18 Buy4 Hold0 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportJul 31, 2026Jun 2026
Consensus EPS$3.665 estimates
Expected range$3.59–$3.81Low to high EPS
Dec 2026$14.16Street EPS consensus
Dec 2027$16.19Street EPS consensus
Dec 2028$17.80Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue+8.6% YoY$61.16B$56.33B
Operating income$15.08B$9.14B
Net income$4.23B$4.28B
Operating cash flow$19.03B$18.81B
Capital expenditures($1.21B)($0.97B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

Zacks

Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?

Zacks

Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?

Zacks

Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.